8-K
filed November 7, 2024, 6:59 PM ET
ticker SYRE
CIK 0001636282
earnings
confidence high
sentiment neutral
materiality 0.65
Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end
Spyre Therapeutics, Inc.
2024-Q3 EPS reported
-$3.43
- Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.
- Cash, cash equivalents and marketable securities of $414.2M as of Sep 30, 2024; runway extended well into 2027.
- SPY001 Phase 1 interim data expected by year-end 2024; SPY002 FIH trials initiated in Q4 2024.
- Appointed Sheldon Sloan, M.D., as Chief Medical Officer, effective October 2024.
- Preclinical data for SPY003 at UEGW showed >3-fold half-life extension vs risankizumab; FIH accelerated to Q1 2025.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001636282-24-000085
- form_type
- 8-K
- ticker
- SYRE
- cik
- 0001636282
- company_name
- Spyre Therapeutics, Inc.
- filed_at
- 2024-11-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:09.057672+00:00
- generated_at
- 2026-05-30T03:36:28.764179+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001636282-24-000085
- json_url
- https://secwatch.observer/filing/0001636282-24-000085.json
- markdown_url
- https://secwatch.observer/filing/0001636282-24-000085.md
- text_url
- https://secwatch.observer/filing/0001636282-24-000085.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1636282/000163628224000085/0001636282-24-000085-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1636282/000163628224000085/syre-20241107.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
RMCF
Rocky Mountain Chocolate Factory Q4 revenue down 24% to $6.8M; net loss per share widens to $0.38
Rocky Mountain Chocolate Factory, Inc.
June 1, 2026, 9:15 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
FNGR
FingerMotion FY2026 revenue down 32% to $24.1M; net loss widens to $7.0M
FingerMotion, Inc.
May 29, 2026, 5:12 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PKE
Park Aerospace Q4 sales up 43% to $24.2M; EPS $0.19 vs $0.06 YoY; full-year net earnings double to $11.3M
PARK AEROSPACE CORP
May 28, 2026, 4:29 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PLUS
ePlus Q4 net sales +20.6% to $576M, diluted EPS $0.78; FY2026 net sales +22.1% to $2.44B; dividend raised to $0.27
EPLUS INC
May 28, 2026, 4:25 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
VSAT
Viasat FY2026 revenue $4.6B record; net loss narrows to $34M; Adj EBITDA $1.6B record
VIASAT INC
May 28, 2026, 4:23 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.